Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11491205 Biased IL2 muteins methods and compositions

Patent 11491205 was granted and assigned to Synthekine on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 8, 2022

Patent Application Number

17149405

Date Filed

January 14, 2021

Patent Citations

US Patent 10166257 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

US Patent 10174091 IL-2 muteins

US Patent 10183980 Superagonists and antagonists of interleukin-2

US Patent 10654905 Method of treating graft versus host disease with an interleukin-2 mutein

US Patent 10293028 Use of low dose IL-2 for treating autoimmune related or inflammatory disorders

US Patent 10010587 IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

US Patent 10035836 Modified IL-2 variants that selectively activate regulatory T cells

US Patent 10086046 Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells

...

Patent Primary Examiner

Karen A. Canella

CPC Code

The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11491205 Biased IL2 muteins methods and compositions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool